• De Groot to speak at ASCLS-CNE event

    Posted on April 24, 2014 by Anthony Marcello
    APRIL 24, 2014 EpiVax CEO/CSO, Dr. Annie De Groot MD, will be one of the featured speakers during next week’s 66th Annual Clinical Laboratory Science Convention. The event is scheduled for April 29 through May 1 at the Rhode Island Convention Center in Providence. Dr. De Groot will speak on Tuesday, April 29 during a workshop on ...
    Read more
  • URI & EpiVax scientists – closer to designing vaccine for H. pylori pathogen

    Posted on April 21, 2014 by Anthony Marcello
    Providence, R.I. – April 18, 2014 – Researchers from the University of Rhode Island and EpiVax, Inc. are championing a recent breakthrough in the laboratory with the hopes it could lead to a vaccine against the pathogen responsible for stomach cancer and other ailments. The results are published today in the Public Library of Science One ...
    Read more
  • Immunogenicity and Tolerance Seminar – Amsterdam 2016

    Posted on April 1, 2014 by Steven Vessella
    Platine ​and ​EpiVax are ​co-organizing ​their ​2nd ​seminar on Immunogenicity and Tolerance on October 24th, 2016. Click this link to register This meeting will focus on the determinants of immunogenicity – a key feature of effective vaccines and a key barrier to success in the clinic for protein therapeutics. Conversely, tolerance induction is a key feature of successful protein therapeutics, while ...
    Read more
  • ICoVax 2013 papers are now published

    Posted on March 19, 2014 by Anthony Marcello
    IcoVax Update: The publications from our “ICoVax 2013” pre-conference have now been published. The full content of the supplement can be found at this link. The link to the supplement is permanently accessible. We hope to see you at the next event! ICoVax description: The annual Vaccine & ISV Annual Global Congress, co-organized by the Vaccine journal and the International ...
    Read more
  • Now in Malaysia: "Stealth" virus H7N9

    Posted on February 13, 2014 by Anthony Marcello
    From CIDRAP: Stealth Virus Moves in on Malaysia. This is the first case reported outside of China/Hong Kong; more are expected. The case fatality rate is currently at 24%. Health officials announced an H7N9 avian flu infection in Malaysia today, the first case detected outside of China, along with eight other newly confirmed cases—one in Hong ...
    Read more
  • Science: Avian Flu Concerns Shutter Poultry Markets

    Posted on January 29, 2014 by Anthony Marcello
    Avian Flu Concerns Shutter Poultry Markets 28 January 2014 4:15 pm 0 Comments M M (Padmanaba01)/Wikimedia CommonsFlu source? A poultry market in China. WASHINGTON, D.C.—With human cases of H7N9 avian influenza piling up, Chinese authorities have ordered the closure of live poultry markets in three eastern cities in a bid to stem transmission of the virus. So far, the Chinese ...
    Read more
  • PBN: New research, same mission: ‘improve human health’

    Posted on January 22, 2014 by Anthony Marcello
    New research, same mission: ‘improve human health’ EPI CENTER: EpiVax founder and CEO Anne S. De Groot described herself as a “physician to make products that help human health everywhere.” PBN PHOTO/MICHAEL PERSSON By Harold Ambler Contributing Writer 1/13/14 If “immunoinformatics” ever becomes a household word, the team at Providence’s EpiVax Inc., led by CEO Dr. Anne S. De ...
    Read more
  • . . . #ToldYouSo – EpiVax H7N9 ‘Stealth Virus’ Prediction a Slam Dunk

    Posted on January 4, 2014 by Annie De Groot
    Add two previous reports of the low immunogenicity of H7N9 HA, one from NovaVax, stating that their unadjuvanted vaccine is only 6-16% effective and Novartis – showing only 6% seroconversion for their unadjuvanted HA vaccine) to this report – and you have a slam dunk – three independent verifications that our tools accurately predict vaccine ...
    Read more
  • Employment Opportunities at a Cutting Edge Biotech Company in Providence

    Posted on January 4, 2014 by Anthony Marcello
    Why work at EpiVax? Members of the EpiVax team strive to see beyond the horizon, desiring to be part of an effort that is bigger than themselves by contributing to improving human health by moving science forward.  In the long term, we aim to leave behind a legacy for the next generation, and we therefore continually ...
    Read more
  • H7N9 is back – now in Hong Kong (& Shenzhen, China)

    Posted on December 8, 2013 by Annie De Groot
    Date: Sun 8 Dec 2013 Story communicated by and reposted from: ProMED-mail South China Morning Post 19 people who came into contact with Hong Kong’s 2nd H7N9 flu patient are being kept in isolation in a hospital and at a holiday camp. They include 13 Tuen Mun Hospital patients who were being cared for in beds close to the 80-year-old man when ...
    Read more
  • EpiVax Receives More Funding for Pompe's Research

    Posted on December 5, 2013 by Anthony Marcello
    Seven RI Companies Receive $314,930 in SBIR Phase I Matching Grants Published on December 5, 2013 Seven Rhode Island companies are the first recipients of the Innovate Rhode Island Small Business Fund (IRISBF) matching grants for federal Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) grant recipients.  These firms have already received over $1.2 ...
    Read more
  • Biotest-EpiVax Collaborative Research Targets New, Non-Immunogenic Treatment for Hemophilia A (Full Article)

    Posted on December 3, 2013 by Anthony Marcello
    Biotest-EpiVax Collaborative Research Targets New, Non-Immunogenic Treatment for Hemophilia A Dreieich/ Germany, Rhode Island/ USA, 3 December 2013. Biotest AG, Dreieich, Germany and EpiVax, Inc., Providence, Rhode Island, USA are pleased to announce a new Collaborative Research Agreement. With this collaboration a novel, non-immunogenic Factor VIII (FVIII) should be developed. The coagulation factor VIII used for ...
    Read more
  • Beyond Humanization: New EpiVax Publication (Open Access)

    Posted on November 26, 2013 by Anthony Marcello
    Beyond humanization and de-immunization: tolerization as a method for reducing the immunogenicity of biologics Expert Rev. Clin. Pharmacol. 6(6), 651–662 (2013) Abstract Immune responses to some monoclonal antibodies (mAbs) and biologic proteins interfere with their efficacy due to the development of anti-drug antibodies (ADA). In the case of mAbs, most ADA target ‘foreign’ sequences present in the complementarity determining regions (CDRs). ...
    Read more
  • Dr. Alan Rothman of iCubed Discusses new $21.4M in Grants for URI

    Posted on October 4, 2013 by Anthony Marcello
    Dr. Alan Rothman of iCubed discusses two large grants, totaling $21.4 million dollars for The University of Rhode Island. He also comments on the current status of the government and the effects on academic groups obtaining grants. (interview starts at 1:15) Read the original PBN article on this topic. // _ // ]]>//
    Read more
  • EpiVax commits resources to bring its Tregitope platform to clinic

    Posted on September 25, 2013 by Anthony Marcello EpiVax commits resources to bring its Tregitope platform to clinic A pioneering firm in immunogenicity comes of age PHOTO BY SCOTT KINGSLEY Dr. Anne S. De Groot, CEO of EpiVax, Inc., is one of the original biotech pioneers in Rhode Island. Her firm’s slogan is “Science without Fear.” By Richard Asinof Posted 9/21/13 PROVIDENCE – At age 15, EpiVax is one of ...
    Read more

Join our newsletter

We strive to provide our clients, collaborators and everyday immunology enthusiasts with valuable content.  Written by our CEO/CSO Dr. Anne Dr Groot, you can expect up to date vaccine development efforts, upcoming events and so much more from our offices here in Providence, RI.

Click Here